Tonix Pharmaceuticals Presented Data On Its Potential Mpox Vaccine TNX-801 In "Using Synthetic Biology To Battle Mpox" Talk At Immunology Symposium At The University Of Alberta, TNX-801 Vaccination Demonstrated Efficacy In Protecting Animals From Lethal Challenge With Clade I Mpox
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals presented promising data on its potential Mpox vaccine, TNX-801, at an immunology symposium. The vaccine showed efficacy in protecting animals and improved tolerability in immunocompromised subjects. It has been selected by NIH's Project NextGen for clinical testing.
September 09, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' TNX-801 vaccine demonstrated efficacy in protecting animals from Mpox and improved tolerability in immunocompromised animals. It has been selected for clinical testing by NIH's Project NextGen.
The presentation of positive data on TNX-801, including its efficacy and improved tolerability, is a significant development for Tonix Pharmaceuticals. The selection by NIH's Project NextGen for clinical testing further validates the potential of the vaccine, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100